AI-driven digital twins enhance drug discovery and testing efficiency

AI technology is advancing drug discovery by creating digital twins, which are computer-generated models of human organs. These digital twins can simulate various health conditions and demographics, allowing for more diverse and thorough testing of medical devices without the limitations of traditional clinical trials. Companies like Adsilico and Sanofi are using these digital models to improve safety and efficiency in testing. Adsilico's digital hearts can replicate thousands of patient scenarios, while Sanofi's AI-generated patients help predict drug reactions, potentially reducing testing time and costs significantly. Despite the promise of digital twins, challenges remain. The effectiveness of these models depends on the quality of the data used to create them. Companies are working to enhance their data sources to ensure accurate and representative simulations in drug and device testing.